|
The said EIR has been issued in relation to the US Food & Drugs Administration (US FDA) audit that was conducted in the month of October 2023.
"No 483' s were issued during the audit,” Marksans Pharma said in a statement.
Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.
On consolidated basis, the company's net profit jumped 15% to Rs 68.66 crore during the quarter as compared with Rs 59.72 crore posted in corresponding quarter last year. Net sales increased 15.3% year on year to Rs 500.03 crore in Q1 FY24 over Q1 FY23.
|